Medicine Grade High Purity 99% Lenalidomide CAS 191732-72-6

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: Frazer-Lenalidomide
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: White Powder
• Purity: >99%
• Appearance: White Powder
• Shelf Life: 2 Years
• Storage: Keep in Cool and Dry Place
• Delivery: Express 5-7 Days Arrive
• Test Method: HPLC
• Assay: 99%
• MOQ: 1kg
• Shipping Area: Worldwide/All Countries
• CAS: 191732-72-6
• Service: Good Service
• Delivery Method: FedEx/DHL/Special Line
• Mf: C13h13n3o3
• Transport Package: Foil Bag
• Specification: 99%
• Trademark: Xi′an Frazer Biotech Co., Ltd.
• Origin: China
• Production Capacity: 200kg Per Month

Product Description

Medicine Grade High Purity 99% Lenalidomide CAS 191732-72-6

 

Specification of Analysis

Items	Standard	Result
Appearance	White to yellow crystalline powder	Complies
Chloride	0.05% max	Complies
Identification	A: It should from a red precipitate B: max absorption at 306 nm wavelength of min absorption at 274 nm wavelength C: IR	Complies   Complies Complies
Loss on drying	0.5% max	0.02%
Residue on ignition	0.1% max	0.05%
Related substances	Impurity A                 0.1% max Impurity B                 0.1% max Any single impurity          0.1% max Total impurities             0.5% max	ND ND 0.01% 0.04%
Residual solvent	N,N-dimethylformamid       0.088% max E'thyl acetate                0.5%max M'ethanol                   0.3% max	ND ND 0.03%
Heavy metal	10 ppm max	Complies
Assay	98.5% min	100.1%
Conclusion	It conforms to the specification

Despcription

Lenalidomide is a thalidomide analog with potential antineoplastic activity. Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growt-h fact-or and basic fibroblast grow-th factor (bFGF), and inhibits angiogenesis. This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.

Function

Lenalidomide is indicated for the treatment of multiple myeloma in combination with d'examethasone. It is also indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.